To print: Select File and then Print from your browser's menu

Title: Fluconazole, Itraconazole Equally Effective In Vulvovaginal Candidiasis

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12551791&dopt=Abstract

Eur J Obstet Gynecol Reprod Biol 2003 Feb;106:2:193-7. "Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study."
02/07/2003 09:10:28 AM
By Anne MacLennan

Both fluconazole and itraconazole produce dramatic results within one week in women with acute vulvovaginal candidiasis (VVC), suggest researchers in Italy. This study, from three university centres, found that each of the two oral antifungal agents showed good clinical and mycological efficacy on the acute VVC episode, achieving significant decrease of signs and symptoms after seven days of treatment. Led by Dr C De Punzio from the Universita degli Studi di Pisa, these investigators compared safety and efficacy of fluconazole 150mg single dose and itraconazole 200mg per day for three days in 86 patients. All of the patients in the double-blind randomised study had acute clinically and mycologically confirmed VVC. Of the 86, a total of 70 -- 38 on fluconazole and 32 on itraconazole -- were able to be evaluated. By day 7, all but one of the fluconazole patients were cured or improved, and there was eradication of the baseline pathogen in all but two patients on itraconazole. At day 21, a 13% relapse rate was observed in both groups, with all other patients cured or improved and eradication rates of 76% for fluconazole and 66% for itraconazole. Although global symptom scores (GSS) were significantly more severe at baseline in fluconazole patients, the slope of the GSS decrease between baseline and day seven was similar for both groups and, on the last visit, GSS were identical. As for adverse events, 19 fluconazole patients reported 31, and 15 itraconazole patients reported 30. The authors point out fluconazole in single dose warrants optimal compliance in patients who frequently experience more than one episode of VVC.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12551791&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.